Akeso has announced that the National Medical Products Administration (NMPA) has accepted its supplemental New Drug Application (sNDA) for gumokimab (AK111), a humanized anti-IL-17A monoclonal antibody, for the treatment of active ankylosing spondylitis (AS). The filing, supported by a pivotal Phase 3 trial, marks the second NDA submission for gumokimab, following its earlier psoriasis application in 2025.

What this reveals about Akeso’s ambition in non-oncology immunology markets

This filing marks a strategic inflection point for Akeso, historically perceived as an oncology-centric developer, now aggressively expanding into autoimmune diseases. Gumokimab becomes the third asset from its non-oncology portfolio to reach the regulatory review stage, joining ebronucimab (targeting PCSK9) and ebdarokimab (an IL-12/IL-23 agent). Notably, both of those assets have not only secured approvals but also achieved reimbursement status through inclusion on China’s National Reimbursement Drug List (NRDL).

Akeso’s intent to become a serious player in autoimmune disease is not speculative—it is already being operationalized. The company is simultaneously advancing manfidokimab (IL-4R) and first-in-class programs like AK139, a bispecific IL-4Rα/ST2 antibody, and AK152, positioned for neurodegenerative indications. These programs reflect Akeso’s broader pipeline strategy: develop and file clinically differentiated immunomodulators, with rapid commercial follow-through.

Why IL-17A remains a clinically validated but commercially crowded target

IL-17A inhibition is a well-established mechanism in spondyloarthritides like AS and psoriatic arthritis. Global leaders in this space include secukinumab (Cosentyx) from Novartis and ixekizumab (Taltz) from Eli Lilly and Company. In China, these agents already have approval and market presence, with pricing and access dynamics shaped by NRDL inclusion and increasing biosimilar activity.

What distinguishes gumokimab, according to Akeso’s trial disclosures, is its apparent early onset of action and consistent efficacy across subgroups in the AK111-303 study. The study achieved statistical and clinical significance across primary (ASAS20) and secondary (ASAS40) endpoints. Industry observers note that while these are standard efficacy measures in AS trials, the emphasis on quality-of-life improvement and functional metrics suggests Akeso is aiming to compete not just on efficacy but on patient-reported outcomes and convenience.

However, therapeutic differentiation in the IL-17 space remains subtle. Clinicians tracking the field believe switching between IL-17A inhibitors often yields similar outcomes, barring tolerability issues. For gumokimab to capture share in the presence of entrenched global brands, Akeso will likely need to either underprice aggressively or demonstrate advantages in administration frequency, immunogenicity, or real-world effectiveness.

What regulators and payers may watch in gumokimab’s review trajectory

The NMPA’s Center for Drug Evaluation (CDE) has demonstrated increasing efficiency in assessing biologics for autoimmune conditions, especially those backed by Phase 3 data. Gumokimab’s psoriasis NDA was accepted in January 2025, offering a reference timeline for regulatory watchers to benchmark this new AS review process.

Key questions for regulators may include the depth of long-term safety data—particularly given IL-17 inhibition’s known association with mucocutaneous candidiasis and potential exacerbation of inflammatory bowel disease. Industry analysts expect safety differentiation, if any, to be marginal, unless Akeso can present lower adverse event rates relative to competitors in real-world follow-up.

From a payer standpoint, the benchmark will likely be gumokimab’s positioning versus existing NRDL-listed IL-17 inhibitors. If Akeso pursues rapid NRDL inclusion post-approval, the drug could access China’s estimated 4 million AS patients, many of whom remain untreated or inadequately controlled on conventional agents such as NSAIDs and TNF blockers.

What remains unproven despite positive Phase 3 results

While the AK111-303 trial hit all its primary and secondary endpoints, the absence of head-to-head data against secukinumab or ixekizumab leaves open questions about comparative performance. This is not unusual in China’s regulatory environment, where bridging studies and domestic comparator arms are not always mandated. However, for broader physician adoption—especially among rheumatologists trained on Western guidelines—such data could prove crucial.

Manufacturing scalability is another potential bottleneck. Akeso has made public statements about its GMP-compliant production capabilities, but the actual commercial supply capacity for gumokimab has not been disclosed in detail. For an agent targeting millions of patients, batch consistency, cold-chain logistics, and parallel ramp-up for two indications (psoriasis and AS) could test the company’s downstream infrastructure.

Finally, analysts have flagged the potential saturation risk in IL-17 therapies. With global and regional biosimilars of secukinumab already emerging, any pricing premium Akeso targets may be eroded quickly unless supported by compelling pharmacoeconomic data.

What this signals about China’s evolving autoimmune drug development landscape

Akeso’s pipeline trajectory mirrors a broader shift in China’s biologics sector—from oncology-first strategies to multi-indication immunology platforms. The country’s regulatory body has also signaled openness to accelerated pathways for autoimmune and inflammatory conditions, especially where unmet needs or population-scale disease burdens are evident.

Clinicians and industry observers alike are watching to see whether Chinese-developed biologics can not only meet Western efficacy standards but also adapt more quickly to China-specific disease phenotypes, treatment adherence challenges, and public insurance dynamics. Gumokimab’s parallel development in psoriasis and AS makes it a compelling case study in pipeline synergies and lifecycle management across indications.

More broadly, Akeso’s success or failure in this space could set a precedent for other domestic biopharmaceutical firms weighing the pivot to immunology—especially in the IL and JAK inhibitor spaces, where licensing deals and internal R&D are ramping up.

What to watch next as Akeso prepares for regulatory decision

The next visible milestone will likely be the outcome of the psoriasis NDA, which could offer an early indication of the CDE’s view on gumokimab’s safety and consistency. A successful approval there would strengthen the case for AS approval, especially if coupled with pricing guidance or NRDL inclusion prospects.

Meanwhile, industry observers are closely tracking Akeso’s ability to fund, manufacture, and scale a dual-indication launch, particularly given the margin pressures of China’s increasingly competitive biologics landscape. Investors will be watching not just for regulatory clearance but also for signal on payer uptake, prescriber confidence, and commercial execution capacity.

In the absence of head-to-head trial data or global commercialization plans, gumokimab remains a domestically ambitious but externally unvalidated program. Still, its progress marks a significant step for China’s self-sufficiency in autoimmune biologics, and a meaningful test of Akeso’s evolution into a multi-vertical biopharmaceutical contender.

  AK111, Akeso, ankylosing spondylitis, autoimmune disease, biologics, China pharma, gumokimab, IL-17A inhibitor, monoclonal antibody, NMPA, Spondyloarthritis